Introduction
============

Hemophilia is a rare disease that is characterized by a tendency of bleeding due to congenital deficiency of blood coagulation factor activity. Hemophilia A and B are the different types of the disease caused by the dysfunction of different coagulation factors. Patients with hemophilia may need surgical treatment for other diseases, and this requires consideration of pathologies caused by bleeding associated with hemophilia. The number of patients with hemophilia undergoing surgery is increasing annually, while bleeding problems in young patients are decreasing due to the development of hemostasis treatments. These factors have combined to improve life prognosis and increase the number of patients with hemophilia.

Surgical procedures inevitably result in bleeding, and excessive blood loss is particularly likely in spinal surgery for patients with hemophilia, which causes hesitancy in performing this surgery. There have been no reports on spinal surgery in patients with hemophilia. Here we report our experience of five such patients.

Materials and Methods
=====================

The subjects were five patients (all males) with hemophilia who underwent spinal surgery at Nagoya University Hospital. Two patients had hemophilia A (deficiency of factor VIII) and three had hemophilia B (deficiency of factor IX). Complications included one patient requiring dialysis and three patients with hepatitis C. The mean age at the time of surgery was 63 years (range, 46--73 years). The following surgeries were performed: posterior lumbar interbody fusion (PLIF) in two patients, and lumbar fenestration, cervical laminoplasty and lumbar fenestration, and cervical laminoplasty and PLIF in one patient each. In all the patients, intraoperative hypotensive anesthesia was induced, and cotton fibrillar collagen (Integran; Nippon Zoki Pharmaceutical Co. Ltd., Osaka, Japan) was used for hemostasis. A closed suction drainage system was used in all surgeries. The mean preoperative activated partial thromboplastin time (APTT) was slightly prolonged to 43 seconds (range, 30--58 seconds), and the average preoperative coagulation factor activity was 21% (range, 3%--59%). All factor allogeneic antibodies (inhibitors) were negative. Preoperative and postoperative outcomes and postoperative complications were examined. Preoperative coagulation factor activity was maintained at ≥80% preoperatively to postoperative day (POD) 14, and at ≥50% after POD 15. An initial bolus administration of a single dose of the formulation was performed to obtain the target level, followed by continuous administration at 4--5 U/kg/hr, with consideration of the clearance rate of the factor preparation. This study was approved by the Ethics Committee of Nagoya University Hospital (IRB approval no., 354-3) and informed consent was obtained from all patients.

Results
=======

We summarized five all cases in [Table 1](#t1-asj-2018-12-3-442){ref-type="table"}. Coagulation factor at a mean dose of 4.8 ×10^3^ U (range, 3--6 ×10^3^ U) was intravenously injected just before surgery, followed by continuous administration of 5.2 ×10^3^ U (range, 4--6 ×10^3^ U) in the 24 hours after surgery. The factor activity was maintained at ≥80% until POD 14, and at ≥50% thereafter. The average duration of surgery was 178 minutes (range, 133--233 minutes) and the estimated blood loss was 661 mL (range, 272--1,344 mL). The drain tube was left in place for 2 days, and the average total drainage volume for 2 days was 557 mL (range, 348--760 mL). Two patients received intraoperative blood salvage autotransfusion (IBSA). One patient required autologous and allogeneic blood transfusion (red cell concentrates mannitol adenine phosphate, 2 units). In one patient, reoperation was performed because of postoperative surgical site infection, but there were no complications due to hemorrhagic diathesis. The hospitalization period was 28 days (range, 19--40 days) and all patients were discharged. The total amount of coagulation factor administered during hospitalization was 102 ×10^3^ U (range, 46--198 ×10^3^ U). The average cost of perioperative blood coagulation factors was \$65,000 (range, \$29,000--126,000).

Discussion
==========

Hemophilia is divided into hemophilia A and B, which are caused by qualitative and quantitative abnormalities of blood clotting factors VIII and IX, respectively. Hemophilia is a rare congenital recessive hereditary form of congenital hemorrhagic disease, with about 6,000 cases in Japan. Blood tests indicate prolongation of APTT, and characteristic clinical symptoms include deep bleeding, such as intraarticular and intramuscular bleeding. Advances in the development of blood products now enable factor activity to be maintained using coagulation factor preparations, and it is becoming possible to perform surgery in patients with hemophilia.

Administration of repeated doses of coagulation factor preparations over a prolonged period can lead to the appearance of inhibitors, with inhibitor generation occurring at the rate of 5%--10% in cases of repeated administration of factor preparations in patients with severe hemophilia \[[@b1-asj-2018-12-3-442]\]. An inhibitor will bind to the coagulation factor and cause functional impairment such that the hemostatic effect induced using the supplemented coagulation factors markedly decreases or disappears. Our study did not include patients who exhibited inhibitor development, but it has been reported that massive bleeding can occur despite administration of a coagulation factor preparation due to the presence of inhibitors; thus, it is extremely important to confirm the absence of inhibitors before surgery \[[@b2-asj-2018-12-3-442]\].

A dosage regimen for the coagulation factor preparation should be established after confirming the pharmacokinetics in a test administration of the preparation before the surgery. Coagulation factor preparations may be given by bolus or continuous administration. Safe hemostatic management can be achieved with continuous administration without producing an unnecessarily high coagulation activity or a low trough \[[@b3-asj-2018-12-3-442]\]. The World Federation of Hemophilia Guidelines \[[@b4-asj-2018-12-3-442]\] recommend that an initial bolus administration of a single dose of the formulation is required to obtain the target level, followed by continuous administration at 4--5 U/kg/hr considering the clearance rate of the factor preparation.

In spinal surgery, particular attention is required for intraoperative and perioperative bleeding management, including the risk of postoperative hematoma. In the patients of this study, controlled hypotensive anesthesia, cotton fibrillar collagen for hemostasis, and IBSA were used in combination to reduce intraoperative bleeding as much as possible, and this approach appeared to be effective. Intraoperative and postoperative bleeding were thus controlled with procedures used in normal spinal surgery.

There are reports suggesting that it is possible to reduce bleeding and blood transfusion volumes in spinal surgery by administering tranexamic acid during surgery \[[@b5-asj-2018-12-3-442],[@b6-asj-2018-12-3-442]\]. For patients in whom allogeneic blood transfusion should be avoided, such as pediatric patients, it is important to prepare an adequate volume for autologous blood transfusion. Different techniques can be used for blood conservation, including proper positioning of the patient, muscle paralysis to minimize intra-abdominal pressure, IBSA, and use of antifibrinolytic agents \[[@b5-asj-2018-12-3-442],[@b7-asj-2018-12-3-442]-[@b10-asj-2018-12-3-442]\]. In the postoperative management of patients with hemophilia, cases of massive bleeding have been reported outside the surgical site; thus, it is necessary to pay close attention to the risk of bleeding from non-wound sites \[[@b11-asj-2018-12-3-442],[@b12-asj-2018-12-3-442]\]. Two of our patients with duration of surgery \>200 minutes had intraoperative bleeding of ≥1,000 mL. Therefore, surgeries of longer duration might lead to bleeding even when it is controlled with intravenous administration of coagulation factor, and careful bleeding management is required. However, in our study, controlled hypotensive anesthesia, autologous blood transfusion, and IBSA enabled management of intraoperative and postoperative bleeding.

In terms of medical costs, the use of perioperative blood coagulation factors costs an average of \$65,000, which is very expensive. Simultaneous surgeries on the cervical and lumbar spine were performed in two patients to try to reduce overall invasiveness and to shorten the duration of surgery. The high cost of blood coagulation factors is another reason to avoid multiple surgeries.

Conclusions
===========

In our study, collaboration with a hematologist and an anesthesiologist, and dose adjustment of the coagulation factor preparation to maintain a target level of coagulation factor activity resulted in a good and smooth intraoperative and postoperative course with control of bleeding during and after spinal surgery in patients with hemophilia.

No potential conflict of interest relevant to this article was reported.

Funding was from institutional sources only.

###### 

Summary of the patients in this study

  Patients   Age (yr)   Hemophilia type/inhibitor status   Disease    Procedure   EBL (g)   Op time (min)   Total drainage volume (mL)   Volume of coagulation factor administration   Blood transfusion   Complication                                 
  ---------- ---------- ---------------------------------- ---------- ----------- --------- --------------- ---------------------------- --------------------------------------------- ------------------- -------------- ----- ----------------------- -------------------
  1          73         B/---                              CSM/LSCS   Lam/Fen     199       189             740                          6                                             6                   198            126   ---                     ---
  2          65         A/---                              LSS        Fen         308       120             350                          3                                             4                   46             29    ---                     SSI (reoperation)
  3          50         A/---                              LS         PLIF        1,184     233             760                          5                                             5                   120            76    Autologous/allogeneic   ---
  4          69         B/---                              CSM/LS     Lam/PLIF    1,344     219             590                          5                                             6                   88             56    ---                     ---
  5          46         B/---                              LS         PLIF        272       133             348                          5                                             6                   80             51    ---                     ---

EBL, estimated blood loss; Op, operation; CSM, cervical spondylotic myelopathy; LSCS, lumbar spinal canal stenosis; Lam, laminoplasty; Fen, fenestration; LSS, lumbar spinal stenosis; SSI, surgical site infection; LS, lumbar spondylolisthesis; PLIF, posterior lumbar interbody fusion.
